Hot now
MUMBAI: India's second-largest drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its U.S. business.
The deal is among Dr Reddy's biggest acquisitions, and comes at a time when the company has been facing slowing growth in the United States, its largest market, due to regulatory troubles and fewer new drug approvals.
Some formerly lucrative emerging markets have also taken a hit over the past year, and caused the company´s March quarter profit to slump 86 percent.
The drugs Dr Reddy´s is buying are being divested by Israel-based Teva, the world´s largest maker of generic drugs, to win U.S. antitrust clearance for its $40.5 billion acquisition of Allergan's generic drugs portfolio. The sale to Dr Reddy´s puts Teva a step closer to closing the Allergan deal.
The deal consists of generic drugs awaiting U.S. approval, and some that are already on the market, including "complex generic products across diverse dosage forms", Dr Reddy´s said in a statement.
A trader works on the floor of the New York Stock Exchange , New York City. — AFP/FileNow that US interest rates...
A general view of al-Atba district of the Egyptian capital Cairo. — AFP/FileCAIRO: Egypt appears on track to break...
A man selling vegetables waits for customers at his makeshift stall at Empress Market in Karachi. — ...
A woman shops in a wet market in Kuala Lumpur, Malaysia. — Reuters/FileKUALA LUMPUR: Malaysia's economy grew faster...
The Pakistan Business Forum logo. — Facebook/pbf.limitedISLAMABAD: The Pakistan Business Forum on Saturday called...
US dollar banknotes are seen in this illustration taken March 10, 2023. — ReutersKARACHI: The government plans to...